# Data Extraction Form: CVD Primary Prevention Network Meta-Analysis

## Data Extraction Protocol

### Extraction Team
- **Lead Extractor**: Dr Elena Rodriguez, PharmD
- **Secondary Extractor**: Dr Michael Chen, MD
- **Quality Control**: Dr Priya Sharma, MD, PhD
- **Statistical Review**: Dr James Wilson, PhD

### Version Control
- **Version**: 1.0
- **Date**: October 12, 2025
- **Previous Versions**: None

## General Study Information

### Study Identification
- **Study ID**: [Auto-generated unique identifier]
- **Title**: [Full study title as published]
- **Primary Author**: [Last name of first author]
- **Corresponding Author**: [Contact information if available]
- **Journal/Source**: [Journal name, conference, or source]
- **Publication Year**: [YYYY]
- **DOI**: [Digital Object Identifier]
- **PMID**: [PubMed Identifier]
- **NCT ID**: [ClinicalTrials.gov identifier]
- **Other Registration**: [Other trial registry numbers]

### Study Characteristics
- **Study Design**:
  - [ ] Parallel group RCT
  - [ ] Cluster RCT
  - [ ] Cross-over RCT
  - [ ] Quasi-randomized trial
  - [ ] Other: [Specify]

- **Study Phase**:
  - [ ] Phase 2
  - [ ] Phase 3
  - [ ] Phase 4
  - [ ] Not applicable
  - [ ] Other: [Specify]

- **Blinding**:
  - [ ] Double-blind
  - [ ] Single-blind
  - [ ] Open-label
  - [ ] Not reported

- **Setting**:
  - [ ] Multicenter
  - [ ] Single center
  - [ ] Multinational
  - [ ] Number of centers: [Number]
  - [ ] Countries: [List countries]

- **Study Duration**:
  - [ ] Total study duration: [Months]
  - [ ] Treatment duration: [Months]
  - [ ] Follow-up duration: [Months]

## Population Characteristics

### Inclusion Criteria
- **Age Range**: [Minimum - Maximum years]
- **Sex Distribution**:
  - [ ] Male only
  - [ ] Female only
  - [ ] Both sexes
  - [ ] Male: [N] ([%])
  - [ ] Female: [N] ([%])

### Risk Factors
- **ASCVD Risk Score**:
  - [ ] Mean: [Value] ± [SD]
  - [ ] Median: [Value] (IQR: [Q1-Q3])
  - [ ] Range: [Min-Max]
  - [ ] Risk categories: [e.g., ≥7.5%, ≥10%, etc.]

- **Diabetes Status**:
  - [ ] Type 2 diabetes: [N] ([%])
  - [ ] Duration: [Mean] ± [SD] years
  - [ ] HbA1c: [Mean] ± [SD] %

- **Chronic Kidney Disease**:
  - [ ] CKD present: [N] ([%])
  - [ ] eGFR: [Mean] ± [SD] mL/min/1.73m²
  - [ ] CKD stages: [Distribution]

- **Other Risk Factors**:
  - [ ] Hypertension: [N] ([%])
  - [ ] Current smoking: [N] ([%])
  - [ ] Family history: [N] ([%])
  - [ ] Obesity (BMI ≥30): [N] ([%])

### Baseline Lipid Profile
- **LDL-C**: [Mean] ± [SD] mg/dL
- **HDL-C**: [Mean] ± [SD] mg/dL
- **Total Cholesterol**: [Mean] ± [SD] mg/dL
- **Triglycerides**: [Mean] ± [SD] mg/dL

### Baseline Blood Pressure
- **Systolic BP**: [Mean] ± [SD] mmHg
- **Diastolic BP**: [Mean] ± [SD] mmHg

## Intervention Details

### Treatment Arms
**Arm 1:**
- **Intervention Name**: [Standardized intervention name]
- **Treatment Class**: [Statin, PCSK9i, Lifestyle, etc.]
- **Specific Drug/Dose**:
  - [ ] Atorvastatin [dose] mg daily
  - [ ] Rosuvastatin [dose] mg daily
  - [ ] Evolocumab [dose] [frequency]
  - [ ] Alirocumab [dose] [frequency]
  - [ ] Ezetimibe [dose] mg daily
  - [ ] Polypill: [Components and doses]
  - [ ] Lifestyle: [Specific components]
  - [ ] Other: [Specify]

**Arm 2:**
- **Intervention Name**: [Standardized intervention name]
- **Treatment Class**: [Statin, PCSK9i, Lifestyle, etc.]
- **Specific Drug/Dose**: [Details as above]

**Additional Arms**: [Repeat as needed]

### Control/Comparator
- **Control Type**:
  - [ ] Placebo
  - [ ] Usual care
  - [ ] Active comparator: [Specify]
  - [ ] No intervention

### Concomitant Medications
- **Background Therapy**: [List allowed concomitant medications]
- **Prohibited Medications**: [List prohibited medications]

## Outcome Data

### Primary Outcomes

#### All-Cause Mortality
- **Definition**: [Exact definition used in study]
- **Ascertainment Method**: [How deaths were identified and confirmed]
- **Adjudication**: [Blinded adjudication process]

**Treatment Arm 1:**
- **Events**: [Number of events]
- **Total**: [Number randomized]
- **Percentage**: [Calculated percentage]
- **Follow-up**: [Mean/median follow-up time]

**Treatment Arm 2:**
- **Events**: [Number of events]
- **Total**: [Number randomized]
- **Percentage**: [Calculated percentage]
- **Follow-up**: [Mean/median follow-up time]

**Control/Comparator:**
- **Events**: [Number of events]
- **Total**: [Number randomized]
- **Percentage**: [Calculated percentage]
- **Follow-up**: [Mean/median follow-up time]

#### Major Adverse Cardiovascular Events (MACE)
- **Definition**: [Exact composite definition]
- **Components**:
  - [ ] Cardiovascular death
  - [ ] Myocardial infarction
  - [ ] Stroke
  - [ ] Urgent revascularization
  - [ ] Other: [Specify]

**Treatment Arm 1:**
- **Events**: [Number of events]
- **Total**: [Number randomized]
- **Percentage**: [Calculated percentage]
- **Components Breakdown**: [Individual component counts]

**Treatment Arm 2:**
- **Events**: [Number of events]
- **Total**: [Number randomized]
- **Percentage**: [Calculated percentage]
- **Components Breakdown**: [Individual component counts]

**Control/Comparator:**
- **Events**: [Number of events]
- **Total**: [Number randomized]
- **Percentage**: [Calculated percentage]
- **Components Breakdown**: [Individual component counts]

### Secondary Outcomes

#### Individual Cardiovascular Events
**Myocardial Infarction:**
- **Definition**: [Criteria for MI diagnosis]
- **Classification**: [STEMI/NSTEMI/Other]

**Treatment Arm 1:**
- **Fatal MI**: [N]
- **Non-fatal MI**: [N]
- **Total MI**: [N]

**Treatment Arm 2:**
- **Fatal MI**: [N]
- **Non-fatal MI**: [N]
- **Total MI**: [N]

**Control/Comparator:**
- **Fatal MI**: [N]
- **Non-fatal MI**: [N]
- **Total MI**: [N]

**Stroke:**
- **Definition**: [Criteria for stroke diagnosis]
- **Classification**: [Ischemic/Hemorrhagic/Unknown]

**Treatment Arm 1:**
- **Fatal Stroke**: [N]
- **Non-fatal Stroke**: [N]
- **Total Stroke**: [N]

**Treatment Arm 2:**
- **Fatal Stroke**: [N]
- **Non-fatal Stroke**: [N]
- **Total Stroke**: [N]

**Control/Comparator:**
- **Fatal Stroke**: [N]
- **Non-fatal Stroke**: [N]
- **Total Stroke**: [N]

**Revascularization:**
- **Definition**: [Criteria for revascularization]

**Treatment Arm 1:**
- **PCI**: [N]
- **CABG**: [N]
- **Total Revascularization**: [N]

**Treatment Arm 2:**
- **PCI**: [N]
- **CABG**: [N]
- **Total Revascularization**: [N]

**Control/Comparator:**
- **PCI**: [N]
- **CABG**: [N]
- **Total Revascularization**: [N]

### Safety Outcomes

#### Serious Adverse Events
- **Definition**: [Study definition of SAE]

**Treatment Arm 1:**
- **Total SAEs**: [N]
- **SAE Rate**: [N per 1000 patient-years]
- **Leading SAEs**: [List top 3 with counts]

**Treatment Arm 2:**
- **Total SAEs**: [N]
- **SAE Rate**: [N per 1000 patient-years]
- **Leading SAEs**: [List top 3 with counts]

**Control/Comparator:**
- **Total SAEs**: [N]
- **SAE Rate**: [N per 1000 patient-years]
- **Leading SAEs**: [List top 3 with counts]

#### Drug-Specific Adverse Events

**Statin-Related:**
- **Myopathy**: [N] ([%])
- **Elevated LFTs**: [N] ([%])
- **New-onset Diabetes**: [N] ([%])
- **Treatment Discontinuation**: [N] ([%])

**PCSK9 Inhibitor-Related:**
- **Injection Site Reactions**: [N] ([%])
- **Neurocognitive Effects**: [N] ([%])
- **Hypersensitivity**: [N] ([%])
- **Treatment Discontinuation**: [N] ([%])

**Anti-platelet Related:**
- **Major Bleeding**: [N] ([%])
- **Minor Bleeding**: [N] ([%])
- **Gastrointestinal Bleeding**: [N] ([%])
- **Treatment Discontinuation**: [N] ([%])

### Patient-Reported Outcomes

#### Quality of Life
- **Instrument Used**: [SF-36, EQ-5D, other]
- **Baseline Score**: [Mean ± SD]
- **Follow-up Score**: [Mean ± SD]
- **Change from Baseline**: [Mean difference ± SD]

#### Treatment Satisfaction
- **Adherence Rate**: [Percentage]
- **Treatment Satisfaction Score**: [Mean ± SD]
- **Willingness to Continue**: [N] ([%])

## Risk of Bias Assessment

### RoB 2.0 Domains (for RCTs)

#### Randomization Process
- **Random Sequence Generation**:
  - [ ] Adequate (computer-generated, random table)
  - [ ] Inadequate (alternate assignment, date of birth)
  - [ ] Unclear

- **Allocation Concealment**:
  - [ ] Adequate (central allocation, sealed envelopes)
  - [ ] Inadequate (open allocation)
  - [ ] Unclear

#### Deviations from Intended Interventions
- **Blinding of Participants/Personnel**:
  - [ ] Adequate
  - [ ] Inadequate
  - [ ] Unclear

- **Blinding of Outcome Assessors**:
  - [ ] Adequate
  - [ ] Inadequate
  - [ ] Unclear

#### Missing Outcome Data
- **Completeness of Follow-up**:
  - [ ] <5% missing
  - [ ] 5-10% missing
  - [ ] >10% missing
  - [ ] Unclear

- **Handling of Missing Data**:
  - [ ] Appropriate (ITT analysis, multiple imputation)
  - [ ] Inappropriate (complete case analysis)
  - [ ] Unclear

#### Measurement of Outcomes
- **Outcome Assessment Methods**:
  - [ ] Objective (blinded adjudication, lab values)
  - [ ] Subjective (patient-reported)
  - [ ] Mixed

#### Selective Reporting
- **Protocol Availability**:
  - [ ] Registered protocol available
  - [ ] No protocol available
  - [ ] Unclear

- **Outcome Reporting**:
  - [ ] All pre-specified outcomes reported
  - [ ] Some outcomes missing
  - [ ] Unclear

### Overall Risk of Bias
- [ ] Low risk of bias
- [ ] Some concerns
- [ ] High risk of bias

## Funding and Conflicts of Interest

### Funding Source
- **Primary Funding**:
  - [ ] Government agency
  - [ ] Pharmaceutical industry
  - [ ] Academic institution
  - [ ] Non-profit organization
  - [ ] Mixed funding
  - [ ] Not reported

- **Grant Numbers**: [List if available]
- **Funding Amount**: [If reported]

### Author Conflicts of Interest
- **Financial Conflicts**:
  - [ ] None declared
  - [ ] Honoraria from pharmaceutical companies
  - [ ] Research funding from industry
  - [ ] Stock ownership
  - [ ] Other: [Specify]

- **Non-Financial Conflicts**:
  - [ ] None declared
  - [ ] Academic advancement
  - [ ] Personal relationships
  - [ ] Other: [Specify]

### Study Registration
- **ClinicalTrials.gov**: [NCT number]
- **Other Registries**: [List other registration numbers]
- **Protocol Publication**: [DOI or reference]

## Data Quality Assessment

### Completeness of Reporting
- **CONSORT Compliance**:
  - [ ] Full compliance
  - [ ] Partial compliance
  - [ ] Non-compliance

### Statistical Reporting
- **Effect Estimates**: [OR, RR, HR with confidence intervals]
- **P-values**: [Reported/not reported]
- **Confidence Intervals**: [95% CI reported]
- **Number Needed to Treat**: [Reported/calculated]

### Data Availability
- **Individual Patient Data**: [Available/not available]
- **Aggregate Data**: [Available/not available]
- **Supplementary Materials**: [Available/not available]

## Notes and Comments

### Extraction Notes
- [Any issues with data extraction]
- [Unclear or missing information]
- [Assumptions made during extraction]
- [Need for author contact]

### Quality Concerns
- [Any concerns about study quality]
- [Potential sources of bias]
- [Generalizability issues]

### Additional Information
- [Any other relevant information]
- [Cross-references to other studies]
- [Related publications]

## Extraction Validation

### Double Extraction
- **Primary Extractor**: [Name]
- **Secondary Extractor**: [Name]
- **Agreement Level**: [Percentage agreement]
- **Discrepancies**: [Number and nature of discrepancies]
- **Resolution Method**: [How discrepancies were resolved]

### Quality Control
- **Senior Review**: [Conducted/not conducted]
- **Random Sample Check**: [Percentage checked]
- **Data Verification**: [Methods used]

## Signatures

### Extractor Signatures
- **Primary Extractor**: ________________________ Date: ________
- **Secondary Extractor**: ________________________ Date: ________
- **Quality Controller**: ________________________ Date: ________

---

**Form Version**: 1.0
**Last Updated**: October 12, 2025
**Contact**: Dr Elena Rodriguez (elena.rodriguez@cvd-prevention-nma.org)
